New eczema cream tested in teens – early results expected
NCT ID NCT07329101
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested a cream called VC005 in 11 adolescents aged 12 to 18 with mild to moderate eczema. The main goal was to check safety and how the body processes the drug. Researchers measured drug levels in the blood and looked for side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
VC005 cream
What this could lead to
If it works, this could point toward a new topical treatment for eczema in teens.
What could go wrong
This is a very early Phase 1 trial with only 11 participants, so it is too small to prove effectiveness. The main goal is safety, not symptom relief.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS (AD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hangzhou First People's Hospital
Hangzhou, Zhejiang, China